Harduin Leonardo de Oliveira, Barroso Thiago Almeida, Guerra Julia Bandeira, Filippo Márcio Gomes, de Almeida Leonardo Cortizo, Vieira Brunno Ribeiro, Mello Renata Silveira, Galhardo Adriano Martins, Castro-Santos Guilherme de, Virgini-Magalhães Carlos Eduardo, Strogoff-de-Matos Jorge Paulo
Liv Care Centro Clínico, Niterói, Rio de Janeiro, Brazil.
Afya Hospital Dia, Brasília, Distrito Federal, Brazil.
J Vasc Access. 2025 Mar;26(2):510-518. doi: 10.1177/11297298231226259. Epub 2024 Feb 5.
Vascular stenosis commonly leads to dysfunction in hemodialysis vascular access. Although percutaneous transluminal angioplasty is an established treatment, stent utilization has increased in the last decade as an alternative solution to extend the access function. This study evaluated the safety and initial results of a new impermeable covered stent for treating vascular access outflow stenosis.
Investigators retrospectively analyzed 114 hemodialysis patients treated with polytetrafluorethylene-covered stents from September 2018 to September 2022 across four centers. Lesions treated were de novo or restenotic and located in the venous graft anastomosis, outflow segment, cephalic arch, and basilic swing point. Patients were followed by in-person physical examination at 1, 3, and 6 months, and Duplex ultrasound was performed to evaluate the vascular access circuit and in-stent restenosis. The primary efficacy endpoint was target lesion primary patency at 1, 3, and 6 months. Secondary endpoints included access circuit primary patency and secondary patency at 1, 3, and 6 months. The primary safety endpoint was freedom from local or systemic serious adverse events through 30 days post-procedure.
Forty-four patients had thrombosed access at the initial presentation, and 41 patients presented with recurrent stenosis. The target lesion primary patency rates at 1, 3, and 6 months were 100%, 89.4%, and 74%, respectively. The access circuit primary patency rates were 100% at 1 month, 85% at 3 months, and 62.7% at 6 months. The secondary patency rates at 1, 3, and 6 months were 100%, 96.4%, and 94.6%, respectively. In the adjusted multivariate Cox regression analysis, only recurrent lesions and female gender were associated with reduced primary patency rates. No serious adverse event was observed through the first 30 days post-procedure.
In this retrospective analysis, a new covered stent was shown to be safe and effective for treating peripheral outflow stenosis in vascular access.
血管狭窄通常会导致血液透析血管通路功能障碍。尽管经皮腔内血管成形术是一种既定的治疗方法,但在过去十年中,作为延长通路功能的替代解决方案,支架的使用有所增加。本研究评估了一种新型不透水覆膜支架治疗血管通路流出道狭窄的安全性和初步结果。
研究人员回顾性分析了2018年9月至2022年9月期间在四个中心接受聚四氟乙烯覆膜支架治疗的114例血液透析患者。治疗的病变为原发或再狭窄,位于静脉移植物吻合口、流出段、头臂弓和贵要静脉摆动点。在1、3和6个月时对患者进行亲自体格检查,并进行双功超声检查以评估血管通路回路和支架内再狭窄。主要疗效终点是1、3和6个月时靶病变的原发通畅率。次要终点包括1、3和6个月时通路回路的原发通畅率和继发通畅率。主要安全终点是术后30天内无局部或全身严重不良事件。
44例患者在初次就诊时血管通路已形成血栓,41例患者出现复发性狭窄。1、3和6个月时靶病变的原发通畅率分别为100%、89.4%和74%。通路回路的原发通畅率在1个月时为100%,3个月时为85%,6个月时为62.7%。1、3和6个月时的继发通畅率分别为100%、96.4%和94.6%。在调整后的多变量Cox回归分析中,只有复发性病变和女性性别与原发通畅率降低有关。术后前30天未观察到严重不良事件。
在这项回顾性分析中,一种新型覆膜支架被证明对治疗血管通路的外周流出道狭窄是安全有效的。